Viridian’s Tepezza rival racks up second phase 3 win, clearing path to FDA
A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to file for FDA approval next year an...
A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to file for FDA approval next year and challenge Amgen for a blockbuster market.